Abstract
Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen alleles, hemoglobinA1c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific autoantibody in newly diagnosed T1DM patients (duration shorter than half year) was 73% in East China. According to binary logistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell destruction. Autoantibodies can facilitate the identification of classic T1DM from other subtypes and predict the progression of islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the disease, we should take more factors into consideration when identifying type 1 diabetes mellitus.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Achenbach, P., Warncke, K., Reiter, J., Naserke, H.E., Williams, A.J., Bingley, P.J., Bonifacio, E., and Ziegler, A.G. (2004). Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 53, 384–392.
Atkinson, M.A., and Maclaren, N.K. (1994). The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 331, 1428–1436.
Baekkeskov, S., Aanstoot, H.J., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., Folli, F., Richter-Olesen, H., and De Camilli, P. (1990). Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347, 151–156.
Beck, R.W., Tamborlane, W.V., Bergenstal, R.M., Miller, K.M., DuBose, S.N., Hall, C.A., and Network, T.D.E.C. (2012). The T1D exchange clinic registry. J Clin Endocrinol Metab 97, 4383–4389.
Besser, R.E., Shields, B.M., Casas, R., Hattersley, A.T., and Ludvigsson, J. (2013). Lessons from the mixed-meal tolerance test. Diabetes Care, 195–201.
Bingley, P.J., Gale, E.A., and European Nicotinamide Diabetes Intervention Trial, G. (2006). Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 49, 881–890.
Bonifacio, E., Lampasona, V., Genovese, S., Ferrari, M., and Bosi, E. (1995). Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 155, 5419–5426.
Bottazzo, G.F., Florin-Christensen, A., and Doniach, D. (1974). Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2, 1279–1283.
Christie, M.R., Molvig, J., Hawkes, C.J., Carstensen, B., Mandrup-Poulsen, T., and Canadian-European Randomised Control Trial, G. (2002). IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin. Diabetes Care 25, 1192–1197.
Eisenbarth, G.S. (1986). Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314, 1360–1368.
Fourlanos, S., Dotta, F., Greenbaum, C.J., Palmer, J.P., Rolandsson, O., Colman, P.G., and Harrison, L.C. (2005). Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48, 2206–2212.
Gale, E.A.M. (1994). Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43, 1304–1310.
Gerard-Gonzalez, A., Gitelman, S.E., Cheng, P., Dubose, S.N., Miller, K.M., Olson, B.A., Redondo, M.J., Steck, A.K., and Beck, R.W. (2013). Comparison of autoantibody-positive and autoantibodynegative pediatric participants enrolled in the T1D exchange clinic registry. J Diabetes 5, 216–223.
Gillespie, K.M. (2006). Type 1 diabetes: pathogenesis and prevention. CMAJ 175, 165–170.
Gjessing, H.J., Matzen, L.E., Froland, A., and Faber, O.K. (1987). Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics. Diabetes Care 10, 487–490.
Gu, Y., Zhang, M., Chen, H., Wang, Z., Xing, C., Yang, H., Xu, X., Liu, Y., Zhou, Z., Yu, L., Hutton, J., Eisenbarth, G., and Yang, T. (2011). Discordant association of islet autoantibodies with high-risk HLA genes in Chinese type 1 diabetes. Diabetes Metab Res Rev 27, 899–905.
Hagopian, W.A., Erlich, H., Lernmark, A., Rewers, M., Ziegler, A.G., Simell, O., Akolkar, B., Vogt, R., Jr., Blair, A., Ilonen, J., Krischer, J., She, J., and Group, T.S. (2011). The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes 12, 733–743.
Hawa, M.I., Kolb, H., Schloot, N., Beyan, H., Paschou, S.A., Buzzetti, R., Mauricio, D., De Leiva, A., Yderstraede, K., Beck-Neilsen, H., Tuomilehto, J., Sarti, C., Thivolet, C., Hadden, D., Hunter, S., Schernthaner, G., Scherbaum, W.A., Williams, R., Brophy, S., Pozzilli, P., Leslie, R.D., and Action, L.C. (2013). Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care 36, 908–913.
Nielsen, L.B., Vaziri-Sani, F., Porksen, S., Andersen, M.L., Svensson, J., Bergholdt, R., Pociot, F., Hougaard, P., de Beaufort, C., Castano, L., Mortensen, H.B., Lernmark, A., Hansen, L., and Hvidoere Study Group on Childhood, D. (2011). Relationship between ZnT8Ab, the SLC30A8 gene and disease progression in children with newly diagnosed type 1 diabetes. Autoimmunity 44, 616–623.
Lu, J., Zhou, J., Bao, Y., Chen, T., Zhang, Y., Zhao, A., Qiu, Y., Xie, G., Wang, C., Jia, W., and Jia, W. (2012). Serum metabolic signatures of fulminant type 1 diabetes. J Proteome Res 11, 4705–4711.
Ludvigsson, J., Carlsson, A., Deli, A., Forsander, G., Ivarsson, S.A., Kockum, I., Lindblad, B., Marcus, C., Lernmark, A., and Samuelsson, U. (2013). Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. Diabetes Res Clin Pract 100, 203–209.
Ludvigsson, J., Faresjo, M., Hjorth, M., Axelsson, S., Cheramy, M., Pihl, M., Vaarala, O., Forsander, G., Ivarsson, S., Johansson, C., Lindh, A., Nilsson, N.O., Aman, J., Ortqvist, E., Zerhouni, P., and Casas, R. (2008). GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359, 1909–1920.
Mortensen, H.B., Swift, P.G., Holl, R.W., Hougaard, P., Hansen, L., Bjoerndalen, H., de Beaufort, C.E., Knip, M., and Hvidoere Study Group on Childhood, D. (2010). Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 11, 218–226.
Noble, J.A., Valdes, A.M., Cook, M., Klitz, W., Thomson, G., and Erlich, H.A. (1996). The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 59, 1134–1148.
Orban, T., Sosenko, J.M., Cuthbertson, D., Krischer, J.P., Skyler, J.S., Jackson, R., Yu, L., Palmer, J.P., Schatz, D., Eisenbarth, G., and Diabetes Prevention Trial-Type 1 Study, G. (2009). Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 32, 2269–2274.
Palmer, J.P., Asplin, C.M., Clemons, P., Lyen, K., Tatpati, O., Raghu, P.K., and Paquette, T.L. (1983). Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 222, 1337–1339.
Patterson, C.C., Dahlquist, G., Soltesz, G., Green, A., Europe, E.A.S.G., and Diabetes (2001). Is childhood-onset Type I diabetes a wealth-related disease? An ecological analysis of European incidence rates. Diabetologia 44 Suppl 3, B9–16.
Siljander, H.T., Simell, S., Hekkala, A., Lahde, J., Simell, T., Vahasalo, P., Veijola, R., Ilonen, J., Simell, O., and Knip, M. (2009). Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 58, 2835–2842.
Tridgell, D.M., Spiekerman, C., Wang, R. S., and Greenbaum, C.J. (2011). Interaction of onset and duration of diabetes on the percent of GAD and IA-2 antibody-positive subjects in the type 1 diabetes genetics consortium database. Diabetes Care 34, 988–993.
Verge, C.F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Chase, H.P., and Eisenbarth, G.S. (1996). Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of Type I diabetes. J Autoimmun 9, 379–383.
Wang, J., Miao, D., Babu, S., Yu, J., Barker, J., Klingensmith, G., Rewers, M., Eisenbarth, G.S., and Yu, L. (2007). Prevalence of autoantibody-negative diabetes is not rare at all ages and increases with older age and obesity. J Clin Endocrinol Metab 92, 88–92.
Wasserfall, C.H., and Atkinson, M.A. (2006). Autoantibody markers for the diagnosis and prediction of type 1 diabetes. Autoimmun Rev 5, 424–428.
Wenzlau, J.M., Juhl, K., Yu, L., Moua, O., Sarkar, S.A., Gottlieb, P., Rewers, M., Eisenbarth, G.S., Jensen, J., Davidson, H.W., and Hutton, J.C. (2007). The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104, 17040–17045.
Zhang, L., Gianani, R., Nakayama, M., Liu, E., Kobayashi, M., Baschal, E., Yu, L., Babu, S., Dawson, A., Johnson, K., Jahromi, M., Aly, T., Fain, P., Barker, J., Rewers, M., and Eisenbarth, G.S. (2008). Type 1 diabetes: chronic progressive autoimmune disease. Novartis Found Symp 292, 85–94; discussion 94–88, 122–129, 202–123.
Zhou, Z., Xiang, Y., Ji, L., Jia, W., Ning, G., Huang, G., Yang, L., Lin, J., Liu, Z., Hagopian, W.A., Leslie, R.D., and Group, L.C.S. (2013). Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62, 543–550.
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at link.springer.com
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Liu, J., Bian, L., Ji, L. et al. The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients. Sci. China Life Sci. 59, 930–939 (2016). https://doi.org/10.1007/s11427-016-5052-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-016-5052-3